22. October 2020
Transglutaminase-Newsletter | September 2020
Dear Transglutaminase researchers,
In our current blog Martin Stieler (Zedira’s head of structural biology) provides his perspective on an intriguing question: Can we design an oral FXIIIa blocker? Or is this going to be a “mission impossible”?
Blood coagulation factor XIII is considered being a qualified target for the development of safer anticoagulants. ZED3197 is the first drug-like compound addressing FXIIIa. Its physicochemical features predispose the compound for i.v. application in the acute care setting.
What about a new drug discovery program to design an oral compound? Curious? Then follow the link to learn more about Zedira’s concept for novel oral FXIIIa blockers.
Further, we would like to inform you about our top FXIII products for your research!
Assays and Substrates
Inhibitors
Antibodies
New Zedira blog published about novel oral FXIIIa blockers
Transglutaminase-Newsletter | September 2020Dear Transglutaminase researchers,
In our current blog Martin Stieler (Zedira’s head of structural biology) provides his perspective on an intriguing question: Can we design an oral FXIIIa blocker? Or is this going to be a “mission impossible”?
Blood coagulation factor XIII is considered being a qualified target for the development of safer anticoagulants. ZED3197 is the first drug-like compound addressing FXIIIa. Its physicochemical features predispose the compound for i.v. application in the acute care setting.
What about a new drug discovery program to design an oral compound? Curious? Then follow the link to learn more about Zedira’s concept for novel oral FXIIIa blockers.
Further, we would like to inform you about our top FXIII products for your research!
FXIII
| Art. No. | Name | Unit | Price |
| T027 |
Human blood coagulation Factor XIII-A2, recombinant (hFXIII, A subunit, recombinantly produced in insect cells) |
200 µg | 370 € |
| T070 |
Human Factor XIIIa, Thrombin activated (hFXIIIa, recombinantly produced in insect cells) |
200 µg | 520 € |
| T050 |
Human blood coagulation Factor XIII B subunit (hFXIII B, F13B, recombinantly produced in insect cells) |
200 µg | 370 € |
Assays and Substrates
| Art. No. | Name | Unit | Price |
| A101 |
FXIII-Assay Substance, Abz-NE(CAD-DNP)EQVSPLTLLK-OH |
10 mg |
520 € |
| F001 |
FXIII-Assay Kit (ready to use, contains A101 and thrombin) |
1 Kit |
575 € |
| B010 |
Blood coagulation FXIII-substrate-peptide F11KA (Biotinyl-DQMMLPWPAVAL) |
10 mg |
310 € |
Inhibitors
| Art. No. | Name | Unit | Price |
| T101 |
1,3,4,5-Tetramethyl-2[(2-oxo-propyl)thio] imidazolium chloride |
10 mg |
480 € |
| A108 |
Ac-(D)-Asp-MA-Nle-Nle-Leu-Pro-Trp-Pro-OH (Synonym ZED1301, site specific irreversible inhibitor of FXIII) |
5 mg |
480 € |
Antibodies
| Art. No. | Name | Unit | Price |
| A016 |
Polyclonal antibody to human factor XIII (A-subunit) |
500 µg |
365 € |
| A032 |
FITC-labeled polyclonal antibody to human factor XIII (A-subunit) |
200 µg |
395 € |
| A154 | Monoclonal antibody to human factor XIII (Activation Peptide, clone XTG09) |
200 µg | 365 € |
| A076 |
"DD-XLink-mab" Monoclonal antibody against crosslinked fibrin ("D-dimer") |
100 µg |
365 € |
Successful ISO9001:2015 recertification
Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
Dr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
Design of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering